DGK-κ Inhibitors
DGK-κ inhibitors belong to a distinct chemical class designed to selectively target and inhibit the activity of diacylglycerol kinase kappa (DGK-κ). Diacylglycerol kinases (DGKs) are a family of enzymes crucial for regulating cellular signaling pathways by modulating the levels of diacylglycerol (DAG) and phosphatidic acid (PA), two key lipid messengers. Among the various isoforms of DGKs, DGK-κ stands out for its specific role in immune cell function, particularly in T lymphocytes. DGK-κ inhibitors are synthesized with the aim of modulating immune responses by impeding the enzymatic activity of DGK-κ, thereby influencing downstream signaling cascades.
f DGK-κ inhibitors is meticulously designed to interact with the catalytic site of the DGK-κ enzyme, hindering its ability to phosphorylate diacylglycerol. This inhibition results in the accumulation of diacylglycerol and altered downstream signaling, ultimately impacting immune cell activation and function. The specificity of these inhibitors for DGK-κ sets them apart from other DGK isoforms, highlighting their potential as precise tools for investigating the physiological roles of DGK-κ in immune regulation. The development of DGK-κ inhibitors represents a significant advancement in chemical biology, providing researchers with valuable instruments to dissect the intricate mechanisms underlying immune cell signaling and potentially paving the way for further insights into the modulation of immune responses.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Staurosporine | 62996-74-1 | sc-3510 sc-3510A sc-3510B | 100 µg 1 mg 5 mg | $82.00 $153.00 $396.00 | 113 | |
A potent kinase inhibitor, non-selective, which can inhibit a broad range of kinases including DGKK by blocking their ATP binding sites. | ||||||
PMA | 16561-29-8 | sc-3576 sc-3576A sc-3576B sc-3576C sc-3576D | 1 mg 5 mg 10 mg 25 mg 100 mg | $41.00 $132.00 $214.00 $500.00 $948.00 | 119 | |
An activator of protein kinase C (PKC) which can downregulate DGKK through feedback inhibition mechanisms. | ||||||
Calphostin C | 121263-19-2 | sc-3545 sc-3545A | 100 µg 1 mg | $343.00 $1642.00 | 20 | |
A specific inhibitor of PKC, which can indirectly affect DGKK activity by altering upstream PKC-dependent signaling pathways. | ||||||
Gö 6983 | 133053-19-7 | sc-203432 sc-203432A sc-203432B | 1 mg 5 mg 10 mg | $105.00 $299.00 $474.00 | 15 | |
A PKC inhibitor that can indirectly affect DGKK activity by modulating PKC-mediated signaling cascades. | ||||||
Rottlerin | 82-08-6 | sc-3550 sc-3550B sc-3550A sc-3550C sc-3550D sc-3550E | 10 mg 25 mg 50 mg 1 g 5 g 20 g | $84.00 $166.00 $302.00 $2091.00 $5212.00 $16657.00 | 51 | |
Has been shown to inhibit PKC delta, potentially altering signaling pathways that regulate DGKK activity. | ||||||
Bisindolylmaleimide I (GF 109203X) | 133052-90-1 | sc-24003A sc-24003 | 1 mg 5 mg | $105.00 $242.00 | 36 | |
A selective inhibitor of PKC that may indirectly decrease DGKK activity by inhibiting PKC-mediated signaling. | ||||||
D-erythro-Sphingosine | 123-78-4 | sc-3546 sc-3546A sc-3546B sc-3546C sc-3546D sc-3546E | 10 mg 25 mg 100 mg 1 g 5 g 10 g | $90.00 $194.00 $510.00 $2448.00 $9384.00 $15300.00 | 2 | |
A natural inhibitor of diacylglycerol kinase, potentially reducing DGKK activity by depleting its substrate. | ||||||
Propranolol | 525-66-6 | sc-507425 | 100 mg | $180.00 | ||
A non-selective beta-blocker known to inhibit certain kinases, which might indirectly affect DGKK function. | ||||||
Ruboxistaurin | 169939-94-0 | sc-507364 | 25 mg | $1080.00 | ||
A selective inhibitor of PKC beta, which may indirectly modulate DGKK activity through PKC-dependent pathways. | ||||||